Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 40.4258
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 963348484992.0
- FreeCF/Share 10.0576
- PFCF 106.7931
- PE 52.2408
- Debt/Assets 0.3698
- DivYield 0.0056
- ROE 1.0226
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
News
Eli Lilly's Experimental Weight-Loss Pill Data Disappoints
Published: August 07, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegovy, and Ozempic.
Read More
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Published: August 07, 2025 by: Fast Company
Sentiment: Positive
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used for weight loss, reached nearly $5.2 billion in revenue, up 68% from the same quarter last year and exceeding analyst estimates of $4.7 billion.
Read More
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
Published: August 07, 2025 by: CNBC Television
Sentiment: Negative
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.
Read More
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down
Published: August 07, 2025 by: Forbes
Sentiment: Negative
Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall Street] had.” Orforglipron's average weight loss was “in the range” of what consumers would want to achieve, Ricks said.
Read More
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Negative
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Read More
Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel M. Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology David A.
Read More
Jobless Claims Increased More Than Expected
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Another full morning of market data to go through today, which will help articulate where we are in several accounts of the massive U.S. economy. Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Read More
Top Stock Movers Now: DoorDash, Fortinet, Eli Lilly, and More
Published: August 07, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were mixed at midday as the market continued to focus on earnings, and new U.S. tariffs kicked in. The Nasdaq was up, while the Dow Jones Industrial Average and S&P 500 fell.
Read More
Jobless Claims, Q2 Productivity, Q2 Earnings All Higher
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Read More
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Lilly (LLY) Reports Q2 Earnings: What Key Metrics Have to Say
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
Published: August 07, 2025 by: Investopedia
Sentiment: Negative
Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical firm reported disappointing results from a late-stage study of its experimental obesity pill. The news offset Lilly's strong quarterly results.
Read More
Eli Lilly shares tumble on disappointing weight loss drug trial data
Published: August 07, 2025 by: Proactive Investors
Sentiment: Negative
Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for the company's oral weight loss drug orforglipron drew focus from strong second quarter earnings and raised full-year guidance. The trial showed orforglipron users saw an average weight loss of 12.4% over 72 weeks, which was positive and met the primary endpoint.
Read More
"Disappointment Overall" for LLY Earnings, ABNB Shows Travel Weakness
Published: August 07, 2025 by: Schwab Network
Sentiment: Negative
Eli Lilly's (LLY) earnings beat wasn't enough draw investors in. The bigger focus was on the company's weight loss pill that showed "disappointing" results.
Read More
VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial
Published: August 07, 2025 by: Reuters
Sentiment: Negative
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's injectable obesity treatment Wegovy.
Read More
Top 50 High-Quality Dividend Stocks For August 2025
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.
Read More
There Is Only 1 GLP-1 Stock to Buy In 2025
Published: August 06, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Key Points in This Article: Ozempic's introduction shifted obesity treatment from lifestyle to pharmacological solutions, using GLP-1 drugs to regulate appetite and glucose.
Read More
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Published: August 05, 2025 by: Barrons
Sentiment: Negative
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Insights Into Lilly (LLY) Q2: Wall Street Projections for Key Metrics
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
Read More
Trim Your AI Stocks And Buy Eli Lilly
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
AI and semiconductor stocks are too expensive right now. Don't buy them now, trim your high-tech positions, and buy healthcare stocks like Eli Lilly and Company. LLY is a hyper-growth-at-a-reasonable-price play. A 30% 12-month return is reasonable to anticipate. It is not too early to buy healthcare stocks; it will just require patience. I'd rather leave the party first and miss the traffic than move with the crowd.
Read More
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Published: July 31, 2025 by: Benzinga
Sentiment: Positive
Eli Lilly and Co. LLY released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.
Read More
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS , July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1 …
Read More
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.
Read More
Lilly set for strong quarter after Novo profit warning
Published: July 29, 2025 by: Reuters
Sentiment: Positive
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health.
Read More
The Big 3: OKTA, LLY, ADSK
Published: July 25, 2025 by: Schwab Network
Sentiment: Positive
@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technical breakout," and Autodesk's (ADSK) path to reclaim its 52-week high.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Published: July 24, 2025 by: Business Wire
Sentiment: Neutral
BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales, with a total deal value up to $856 million. The updated release reads: GATE BIOSCIENCE ENTERS INTO A COLLABORATION AND LICENSE AGREE.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000